Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: Current data and clinical outlook

Molecular Diagnosis and Therapy

Volumn 16, Issue 3, 2012, Pages 151-161

  Mateo, Joaquin ^a   Heymach, John V ^a   Zurita, Amado J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Biomarkers; Carcinoid tumour; Everolimus; Interleukin 8; Neuroendocrine tumours; Pancreatic cancer; SDF 1; Sunitinib; Vascular endothelial growth factor; Vascular endothelial growth factor targets

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; BIOLOGICAL MARKER; CHROMOGRANIN A; DRUG METABOLITE; EVEROLIMUS; IMATINIB; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NEURON SPECIFIC ENOLASE; OCTREOTIDE; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; STROMAL CELL DERIVED FACTOR 1ALPHA; SU 012662; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; BONE MARROW CELL; DRUG APPROVAL; DRUG TARGETING; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; HUMAN; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREAS TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; GASTROINTESTINAL NEOPLASMS; HUMANS; INDOLES; INTERLEUKIN-8; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRROLES; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MAMMALIA;

EID: 84861653202     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.2165/11632590-000000000-00000     Document Type: Review

References (72)

1. Bosman FT, Carneiro F, Hruban RH, et al., editors. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer, 2010
2. Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990 Sep 15; 50 (18): 5969-5977
3. Woltering EA, Barrie R, O'Dorisio TM, et al. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 1991 Mar; 50 (3): 245-51
4. Gorden P, Comi RJ, Maton PN, et al. NIH conference: Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989 Jan 1; 110 (1): 35-50
5. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006 Dec; 17 (12): 1733-1742
6. Koizumi M, Onda M, Tanaka N, et al. Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion 2002; 65 (4): 200-6
7. Rinke A, Müller H-H, Schade-Brittinger C, et al. Placebo-controlled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 2009 Oct 1; 27 (28): 4656-4663
8. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced isletcell carcinoma. N Engl J Med 1992 Feb 20; 326 (8): 519-23
9. Cassier PA, Walter T, Eymard B, et al. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: A single-center experience. Cancer 2009 Aug 1; 115 (15): 3392-9
10. Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007 Apr; 59 (5): 637-42
11. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011 Jan 15; 117 (2): 268-75
12. Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.NEngl J Med 2011 Feb 10; 364 (6): 501-13
13. Valle J, Niccoli P, Raoul JL, et al. Updated overall survival data from a phase 3 study of sunitinib vs. placebo in patients with advanced, unresectable pancreatic neuroendocrine tumor (NET) [abstract no. 6569]. European Society for Medical Oncology, European Multidisciplinary Cancer Congress; 2011 Sep 23-27; Stockholm
14. Yao JC, Shah MH, Ito T, et al., for the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors.NEngl J Med 2011 Feb 10; 364 (6): 514-23
15. Kulke MH, Lenz H-J, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008 Jul 10; 26 (20): 3403-3410
16. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 Jan 11; 356 (2): 115-24
17. Demetri GD, Van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006 Oct 14; 368 (9544): 1329-1338
18. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003 Jan; 9 (1): 327-37
19. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006 Jan 1; 24 (1): 25-35
20. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol 2008 Sep 10; 26 (26): 4311-8
21. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011 May 4; 103 (9): 763-73
22. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997 Feb; 18 (1): 4-25
23. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000; 55: 15-36
24. Li X, Eriksson U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int J Biochem Cell Biol 2001 Apr; 33 (4): 421-6
25. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000 Nov 20; 19 (49): 5598-5605
26. DePrimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation ofVEGF and VEGF-related proteins. J Transl Med 2007 Jul 2; 5: 32
27. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006 Jan 1; 24 (1): 16-24
28. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008 Aug 1; 26 (22): 3743-8
29. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008 Apr 10; 26 (11): 1810-6
30. DePrimo SE, Huang X, Blackstein ME, et al. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res 2009 Sep 15; 15 (18): 5869-5877
31. Bellmunt J, González-Larriba JL, Prior C, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatinbased chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011Dec; 22 (12): 2646-2653
32. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 2009 Jun 20; 27 (18): 3027-3035
33. Bello CL, Deprimo SE, Friece C, et al. Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3 [abstract no. 4045]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl.): Abstract 4045
34. Zurita AJ, Heymach JV, Khajavi M, et al. Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors [abstract no. 4079]. J Clin Oncol 2011 May 20; 29 (15 Suppl.): Abstract 4079
35. Zhang J, Jia Z, Li Q, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007 Apr 15; 109 (8): 1478-1486
36. Pavel ME, Hassler G, Baum U, et al. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. Clin Endocrinol (Oxf) 2005 Apr; 62 (4): 434-43
37. Yao JC, Pavel M, Phan AT, et al. ChromograninAand neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 2011 Dec; 96 (12): 3741-9
38. Baudin E, Wolin EM, Castellano D, et al. Correlation of PFS with early response of chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: Phase III RADIANT-2 study results [abstract no. 6564]. European Society for Medical Oncology, European Multidisciplinary Cancer Congress; 2011 Sep 23-27; Stockholm
39. Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998 Feb; 32 (2): 133-8
40. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001 Dec; 12 (4): 375-91
41. Kunz M, Hartmann A, Flory E, et al. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma: A potential mechanism for high tumor aggressiveness. Am J Pathol 1999 Sep; 155 (3): 753-63
42. Inoue K, Slaton JW, Eve BY, et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000 May; 6 (5): 2104-2119
43. Hussain F, Wang J, Ahmed R, et al. The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours. Cytokine 2010 Feb; 49 (2): 134-40
44. Tecimer T, Dlott J, Chuntharapai A, et al. Expression of the chemokine receptor CXCR2 in normal and neoplastic neuroendocrine cells. Arch Pathol Lab Med 2000 Apr; 124 (4): 520-5
45. Li A, Dubey S, Varney ML, et al. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003 Mar 15; 170 (6): 3369-3376
46. Huang S, Mills L, Mian B, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002 Jul; 161 (1): 125-34
47. Huang D, Ding Y, Zhou M, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010 Feb 1; 70 (3): 1063-1071
48. Zheng H, Fu G, Dai T, et al. Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1a/CXCR4 via PI3K/Akt/eNOS signal transduction pathway. J Cardiovasc Pharmacol 2007 Sep; 50 (3): 274-80
49. Kryczek I, Wei S, Keller E, et al. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis.AmJ PhysiolCell Physiol 2007Mar; 292 (3): C987-95
50. Ebos JML, Lee CR, Christensen JG, et al. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 2007 Oct 23; 104 (43): 17069-17074
51. Duda DG, Kozin SV, Kirkpatrick ND, et al. CXCL12 (SDF1a)-CXCR4/CXCR7 pathway inhibition: An emerging sensitizer for anticancer therapies? Clin Cancer Res 2011 Apr 15; 17 (8): 2074-2080
52. Guleng B, Tateishi K, Ohta M, et al. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 2005 Jul 1; 65 (13): 5864-5871
53. Arvidsson Y, Bergstro'm A, Arvidsson L, et al. Hypoxia stimulates CXCR4 signalling in ileal carcinoids. Endocr Relat Cancer 2010 Jun 1; 17 (2): 303-16
54. Beerepoot LV, Mehra N, Vermaat JSP, et al. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004 Jan; 15 (1): 139-45
55. Mancuso P, Burlini A, Pruneri G, et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001 Jun 1; 97 (11): 3658-3661
56. Nolan DJ, Ciarrocchi A, Mellick AS, et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 2007 Jun 15; 21 (12): 1546-1558
57. Gao D, Nolan DJ, Mellick AS, et al. Endothelial progenitor cells control the angiogenic switch inmouse lungmetastasis. Science 2008 Jan 11; 319 (5860): 195-8
58. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997 Feb 14; 275 (5302): 964-7
59. Beaudry P, Force J, Naumov GN, et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005 May 1; 11 (9): 3514-3522
60. Mancuso P, Calleri A, Cassi C, et al. Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 2003; 522: 83-97
61. Khan SS, Solomon MA, McCoy Jr. JP. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 2005 Mar; 64 (1): 1-8
62. Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor165 gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000 Jun 23; 86 (12): 1198-1202
63. Vroling L, Van Der Veldt AAM, De Haas RR, et al. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 2009; 12 (1): 69-79
64. Norden-Zfoni A, Desai J, Manola J, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007 May 1; 13 (9): 2643-2650
65. Fernandez Pujol B, Lucibello FC, Gehling UM, et al. Endothelial-like cells derived from human CD14 positive monocytes. Differentiation 2000 May; 65 (5): 287-300
66. Condeelis J, Pollard JW. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006 Jan 27; 124 (2): 263-6
67. Sawano A, Iwai S, Sakurai Y, et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocytemacrophages in humans. Blood 2001 Feb 1; 97 (3): 785-91
68. Finke J, Ko J, Rini B, et al. MDSC as a mechanism of tumor escape from sunitinib mediated anti-Angiogenic therapy. Int Immunopharmacol 2011 Jul; 11 (7): 856-61
69. Yao JC, Panneerselvam A, Bugarini R, et al. Effect of everolimus treatment on markers of angiogenesis in patients with advanced pancreatic neuroendocrine tumors: Results from the phase III RADIANT-3 study [abstract no. 6573]. European Society for Medical Oncology, European Multidisciplinary Cancer Congress; 2011 Sep 23-27; Stockholm
70. Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A - biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010 Sep; 17 (9): 2427-2443
71. Lawrence B, Gustafsson BI, Kidd M, et al. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011 Mar; 40 (1): 111-34
72. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999 Sep 1; 86 (5): 858-65